The global sexually transmitted disease (STD) diagnostics market was valued at USD 109.02 Billion in 2024 and is projected to reach USD 164.90 Billion by 2033. The market is expected to grow at a CAGR of 4.47% during the forecast period 2025-2033. Growth is driven by rising infection rates, awareness of early diagnosis, and the adoption of at-home testing kits.
Study Assumption Years
Base Year: 2024
Historical Years: 2019-2024
Forecast Period: 2025-2033
Sexually Transmitted Disease (STD) Diagnostics Market Key Takeaways
The global STD diagnostics market size was USD 109.02 Billion in 2024.
The market is forecasted to grow at a CAGR of 4.47% from 2025 to 2033.
North America accounts for over 36.8% market share in 2024.
Increasing prevalence of STDs such as chlamydia, gonorrhea, syphilis, HPV, and HIV is driving demand for early and accurate diagnostics.
Rising awareness and government initiatives encourage routine testing and reduce stigma.
Technological advancements like rapid point-of-care testing, molecular diagnostics, and AI-based tools improve detection accuracy and speed.
The adoption of home-based testing kits and telemedicine services enhances availability and accessibility.
Sample Request Link:
https://www.imarcgroup.com/sexually-transmitted-disease-diagnostics-market/requestsample
Market Growth Factors
The sexually transmitted disease (STD) diagnostics market growth is fueled by rising infection rates globally, with significant increases in chlamydia, gonorrhea, syphilis, HPV, and HIV. Governments and health organizations actively promote screening programs and awareness campaigns to encourage routine testing and destigmatize the process, which propels demand for diagnostic services.
Technological innovations have advanced the field of STD diagnostics significantly. The development of nucleic acid amplification tests (NAATs), rapid diagnostic tests (RDTs), and at-home testing kits offer rapid, accurate, and accessible solutions. These technologies are crucial in regions with limited healthcare access, providing convenient early detection that improves patient outcomes.
Increasing public awareness and government-led initiatives are central to market expansion. Efforts such as the CDC's "Get Yourself Tested" campaign and WHO's target to reduce syphilis cases emphasize early diagnosis and prevention. These programs, along with increased funding for sexual health clinics and research, support the growth and availability of STD diagnostic testing worldwide.
Market Segmentation
By Type:
Chlamydia Testing: Largest segment due to high infection rates and asymptomatic nature, necessitating routine screening especially among sexually active women under 25 years as recommended by CDC and WHO.
Syphilis Testing
Gonorrhea Testing
Herpes Simplex Virus Testing
Human Papilloma Virus Testing
Human Immunodeficiency Virus Testing
Chancroid Testing
Others
By Device Type:
Laboratory Devices: Includes Thermal Cycler – PCR, Lateral Flow Readers, Flow Cytometers, Absorbance Microplate Reader – ELISA, and others. Laboratory devices lead the market because of their accuracy, reliability, and ability to handle large sample volumes for comprehensive testing.
Point of Care (PoC) Devices: Includes Phone Chips (Microfluidics + ICT) and Portable/Bench Top/Rapid Diagnostic Kits.
By End User:
Laboratory Testing: Dominates with 79.8% share due to its comprehensive and accurate testing capabilities using advanced techniques such as PCR, NAATs, and enzyme immunoassays.
Point of Care (PoC) Testing
Regional Insights
North America dominates the STD diagnostics market with over 36.8% share in 2024, driven by high infection rates, advanced healthcare infrastructure, and effective awareness initiatives. The U.S. and Canada have established public health programs promoting regular testing, supported by government funding. Technological progress like PCR diagnostics, AI screening, and at-home testing kits also contribute to market growth.
Recent Developments & News
February 2023: F. Hoffmann-La Roche Ltd. partnered with the CDC to create Lab Networks for Health, aimed at improving HIV and tuberculosis testing and treatment globally in high-burden countries.
February 2023: Mylab developed STD-specific point-of-care tests with reagent-free components requiring no refrigeration, suitable for resource-limited POC facilities.
January 2023: Molbio Diagnostics expanded its STD portfolio with the Truenat HSV 1/2 herpes simplex virus test, delivering results in under one hour and representing a significant advancement in point-of-care testing.
Key Players
Abbott Laboratories
Becton Dickinson and Company
BioMérieux SA
Bio-Rad Laboratories Inc.
Cepheid (Danaher Corporation)
F. Hoffmann-La Roche AG
Hologic Inc.
Qiagen N.V.
Quidel Corporation
Siemens Healthineers AG (Siemens AG)
Ask for Report Customization:
https://www.imarcgroup.com/request?type=report&id=6956&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
